ATC Group: R05DB13 Butamirate

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of R05DB13 in the ATC hierarchy

Level Code Title
1 R Respiratory system
2 R05 Cough and cold preparations
3 R05D Cough suppressants, excl. combinations with expectorants
4 R05DB Other cough suppressants
5 R05DB13 Butamirate

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 25 mg

Active ingredients in R05DB13

Active Ingredient Description
Butamirate

Butamirate (or brospamin) is a cough suppressant. It binds to the cough center in the medulla oblongata, more specifically the dextromethorphan-binding site in guinea pig brain with high affinity.

Related product monographs

Title Information Source Document Type  
BUTAMIRATE Syrup European Medicines Agency (EU) MPI, EU: SmPC
SINECOD Syrup Medicines Authority (MT) MPI, EU: SmPC

Medicines in this ATC group

Croatia (HR)

Cyprus (CY)

Estonia (EE)

Malta (MT)

Romania (RO)

Tunisia (TN)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.